Physician profile
John Alva Simpson
NPI 1417049347
$3,358.96
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $746 · 2021: $1,185 · 2022: $472.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.47 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $513.76 | 2019-2022 | |
| Glaxosmithkline, LLC. | $443.57 | 2019-2022 | |
| Optinose US, INC. | $363.37 | 2019-2021 | |
| Genzyme Corporation | $330.89 | 2019-2022 | |
| Kaleo, INC. | $217.55 | 2019-2022 | |
| Pfizer INC. | $155.09 | 2019-2021 | |
| Genentech USA, INC. | $142.85 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $139.53 | 2020-2022 | |
| Alk-Abello, INC | $79.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.08 | 2019-2022 | |
| Circassia INC. | $29.00 | 2019 | |
| Aimmune Therapeutics, INC. | $22.28 | 2021 | |
| Uswm, LLC | $20.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.29 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.46 | 2021 | |
| Leo Pharma INC. | $17.06 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.